Company News
Zealand Pharma Shares Fall 12% After Trial
Shares of Zealand Pharma plunged up to 12.5% on Thursday after Phase III obesity drug survodutide trial revealed high gastrointestinal discontinuations.
In the 76‑week SYNCHRONIZE‑2 study, patients lo
